Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | VDR | P11473 | 1/20 | 0.43 |
| ▸ | BUB1 | O43683 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927783 | 0.87 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| SCHEMBL16366286 | 0.87 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| SCHEMBL12788095 | 0.84 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| SCHEMBL928140 | 0.82 | PTGER4 (0.50) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| SCHEMBL14584085 | 0.81 | CYP1A2 (0.65) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| SCHEMBL19128354 | 0.81 | CYP1A2 (0.65) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| SCHEMBL12693792 | 0.81 | NPSR1 (0.45) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| SCHEMBL27941734 | 0.81 | CYP1A2 (0.61) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| SCHEMBL927502 | 0.81 | CYP1A2 (0.64) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR | |
| SCHEMBL28662485 | 0.80 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2C9CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3990433-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | Translatum Medicus Inc. (CA) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020261158-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | Translatum Medicus Inc. (CA) | 2020-12-30 | — | — | WO | disclosed |
| EP-2262778-B1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CXCR1 AND P40 | ACRAF (IT) | 2019-08-21 | — | — | EP | disclosed |
| EP-3181551-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40 | Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) | 2017-06-21 | — | — | EP | disclosed |
| EP-2254869-B1 | NEUE 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 UND P40 | ACRAF (IT) | 2017-05-31 | — | — | EP | disclosed |
| US-9255073-B2 | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2016-02-09 | — | — | US | disclosed |
| US-8835481-B2 | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| CN-101965337-B | Novel 1-benzil-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 | ACRAF | 2013-11-06 | — | — | CN | disclosed |
| US-20130267704-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2013-10-10 | — | — | US | disclosed |
| US-8461194-B2 | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A. C. R. A. F. S. P. A. (IT) | 2013-06-11 | — | — | US | disclosed |
| US-20110082141-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIM. RIUN.ANG.FRANC. A.C.R.A.F. S.p.A. (IT) | 2011-04-07 | — | — | US | disclosed |
| US-20110003874-A1 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2011-01-06 | — | — | US | disclosed |
| EP-2262778-A2 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CXCR1 AND P40 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2010-12-22 | — | — | EP | disclosed |
| EP-2254869-A2 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009109616-A2 | NOVEL 1-BENZIL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109613-A2 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2009-09-11 | — | — | WO | disclosed |
| US-20070043057-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043057-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070015771-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070015771-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267704-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | CX3CR1, CCR2, CCR5 | CYP1A2 388/4885CYP3A4 348/4885CYP2C9 674/4885 |
| US-20070015771-A1 | Lonidamine analogs | LONP1, LPXN, QDPR | CYP1A2 4551/4885CYP3A4 4009/4885CYP2C9 4684/4885 |
| US-20110082141-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | CX3CR1, CCR2, CCR5 | CYP1A2 388/4885CYP3A4 348/4885CYP2C9 674/4885 |
| US-20110003874-A1 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | CX3CR1, CCR2, CCR5 | CYP1A2 538/4885CYP3A4 474/4885CYP2C9 868/4885 |
| US-20070043057-A1 | Lonidamine analogs | LONP1, LPXN, QDPR | CYP1A2 4551/4885CYP3A4 4009/4885CYP2C9 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.